High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data.

Hashimoto, Takanao; Ozaki, Akihiko; Bhandari, Divya; Sawano, Toyoaki; Sah, Ranjit; Tanimoto, Tetsuya

Hashimoto, Takanao; Ozaki, Akihiko; Bhandari, Divya; Sawano, Toyoaki; Sah, Ranjit; Tanimoto, Tetsuya.

Hashimoto T; Department of Pharmacy, Sendai City Medical Center, Sendai, Miyagi, Japan.
Ozaki A; Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima 972-8322, Japan.
Bhandari D; Medical Governance Research Institute, Tokyo 108-0074, Japan.
Sawano T; Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima 972-8322, Japan.
Sah R; Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu 44600, Nepal.
Tanimoto T; Internal Medicine, Navitas Clinic Kawasaki, Kanagawa 210-0007, Japan.

J Travel Med ; 28(7)2021 10 11.

Article in English | MEDLINE | ID: covidwho-1462389

Subject(s)

Anaphylaxis; COVID-19; Vaccines; Anaphylaxis/chemically induced; BNT162 Vaccine; COVID-19 Vaccines; Health Personnel; Humans; Japan; RNA, Messenger; SARS-CoV-2; Vaccination; Vaccines/adverse effects

Keywords

BNT162b2 mRNA Covid-19 Vaccine; Japan; anaphylaxis; safety

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 / Anaphylaxis Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal subject: Communicable Diseases / Public Health Year: 2021 Document Type: Article Affiliation country: Jtm

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google